Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Solid Tumors 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Rare Tumour 1Rare Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Intestinal Neoplasms 1Intestinal Diseases 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Genomic Instability 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × alectinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡